Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Tirzepatide is a once-weekly injectable medication designed to help with weight loss and improve blood sugar control
100% achieved 5% or more, 93% achieved 10% or more, and 83% achieved 15% or more in Phase 2
The full-length coding sequence of LtGPX3 and its promoter (1500 bp upstream of the ATG start codon but no stop codon) was amplified from the genomic DNA of strain JMB122 using primers 18F/18R and then used to generate the complementation strain Ltgpx3/ GPX3
its sister brand Mounjaro (same active ingredient tirzepatide) is the version specifically labeled for diabetes management
Future Perspect
The starting dose of tirzepatide is 2.5 mg once a week, and after 4 weeks, the dose is increased to the therapeutic dose of 5 mg and administered subcutaneously in patients with T2D
